A proposed requirement to install CCTV in retail pharmacies selling prescription medicines has triggered a dispute that reaches beyond shop-floor surveillance. The Retail Distribution Chemist Alliance-One Delhi (RDCA One Delhi) has objected to the proposal, arguing that it could record sensitive medical information, impose disproportionate costs on small pharmacies and still fail to establish whether a prescription is valid or a medicine has reached the correct patient.
The Health and Family Welfare Ministry issued the proposed change through GSR 791(E) on September 8, seeking to amend the Drugs Rules, 1945. Under the proposed Rule 65(2A), prescription medicines supplied on the prescription of a registered medical practitioner, excluding wholesale trade, would have to be sold or supplied from licensed premises under CCTV surveillance. The recordings would have to be preserved for at least three months.
RDCA One Delhi has sent an objection letter to the ministry’s Under Secretary (Drugs). Its response places the proposal within two separate policy objectives: monitoring the sale of prescription medicines and protecting the privacy of people who disclose personal health information while buying them. The organisation has asked the ministry to consider a risk-based and proportionate framework and to hold wider stakeholder consultations before issuing a final notification.
The dispute is significant because a pharmacy is not merely a retail counter. According to the chemists’ representation, patients and family members may discuss the dosage of a medicine, how it should be taken and the precautions required. These conversations may involve reproductive and sexual health, mental and neurological conditions, or the healthcare needs of children and older people. In many cases, a family member collects medicines for someone who is not present. A camera could therefore record a person discussing or collecting medicines on behalf of another patient.
That concern is not about whether a camera captures the contents of a prescription alone. It is about the possibility that a recording may connect a person, a pharmacy visit and a health-related conversation. The proposal, as described in the report, does not set out the detailed rules sought by the chemists’ organisation on who may access the footage, whether copies may be made or transferred, how data leaks would be handled, or how recordings would be securely deleted after the retention period.
The central regulatory question is whether CCTV would provide evidence that existing records cannot. RDCA One Delhi has argued that video surveillance can show that a person visited a pharmacy or had a conversation there. It cannot, by itself, confirm the validity of the prescription, determine whether the medicine was clinically appropriate, or establish that it was supplied to the correct patient. Prescription records, bills, registers and other statutory documents already perform distinct functions in the sale and supply process.
This distinction matters for enforcement design. A surveillance requirement may appear to strengthen accountability, but its value depends on what investigators are expected to establish and how the footage can be used. If the policy objective is to trace sales, documentary records may answer one set of questions. If it is to verify conduct at the counter, video may answer another. If it is intended to prevent misuse of prescription medicines, the effectiveness of recording ordinary pharmacy interactions would depend on the safeguards, inspection process and evidentiary standards built into the final rules. The supplied proposal, as reported, does not resolve those operational questions.
The three-month retention period also changes the nature of the compliance burden. A pharmacy would not only need to install cameras. It would need to preserve recordings, maintain the equipment and ensure that footage remains available for the required period. RDCA One Delhi has specifically referred to cameras, electricity, internet connections and digital video or network video recorders as possible sources of technical difficulty. It has asked that temporary failures outside a licensee’s control not automatically be treated as violations.
This is where the proposal becomes an administrative issue for small medical stores. The report records the organisation’s argument that installation and maintenance could create an economic burden, particularly for smaller retailers. The cost is not limited to buying equipment. It can include storage, repairs, power supply, connectivity and procedures for restricting access to footage. A rule that applies uniformly to all licensed premises may therefore have unequal effects depending on the size and resources of the pharmacy.
A risk-based system would approach those differences directly. RDCA One Delhi has asked the ministry to distinguish between levels of risk rather than impose the same surveillance requirement on every retail pharmacy. The report does not provide the ministry’s response to that request or indicate whether the government has accepted, rejected or modified the objections. The proposal therefore remains an open regulatory question rather than a final operating rule.
The institutional structure is also important. The ministry’s proposed amendment would operate through the Drugs Rules, 1945, while compliance would affect licensed retail premises and the records maintained during medicine sales. The proposed framework would consequently sit at the intersection of central rule-making, licensing enforcement and day-to-day pharmacy operations. The final design would determine how responsibilities are divided between the pharmacy owner, staff handling prescriptions, technology vendors and inspecting authorities.
Privacy safeguards would need to be defined with the same precision as the surveillance obligation. The chemists’ organisation has asked for clarity on access, copying, transfer, data leaks and secure deletion after the retention period. Without such provisions, the proposal could establish a retention duty without establishing a complete chain of responsibility for the information being retained. The reported objection does not establish that a breach has occurred; it identifies the possibility of unauthorised use or exposure as a policy risk that the final rules would need to address.
The issue also shows why compliance technology cannot be evaluated only by whether it is technically feasible. A camera can be installed in a shop, but the policy question is what the recording is meant to prove and whether collecting it is proportionate to that purpose. In a pharmacy, the setting contains information that may reveal a person’s medical circumstances even when no formal diagnosis is discussed. The more broadly footage is accessed or shared, the greater the importance of clearly defined safeguards.
At the same time, the proposal reflects a regulatory interest in creating stronger oversight of prescription-drug sales. The source report does not specify the immediate policy trigger for the amendment or provide data on violations that the CCTV requirement is intended to address. It therefore cannot establish whether surveillance would materially improve enforcement. What it does establish is that the proposed rule would add a new layer of monitoring to an activity already associated with prescriptions, bills, registers and other statutory records.
The evidence supplied points to three tests for the final notification. First, the government would need to clarify the precise enforcement purpose of CCTV and how footage would complement, rather than duplicate, existing records. Second, it would need to specify privacy and data-management controls, including access, copying, transfer, breach handling and deletion. Third, it would need to explain how technical failures and the cost of compliance would be treated, particularly for small licensed pharmacies.
Until those details are settled, the most consequential part of the proposal is not the camera itself but the governance framework around it. The debate over CCTV in pharmacies is ultimately about whether a surveillance measure can improve accountability without turning routine access to medicines into a lasting record of private health-related interactions. The ministry’s next step, as sought by RDCA One Delhi, is wider stakeholder consultation before the proposed amendment becomes a final requirement.
